About i2o Therapeutics
i2o Therapeutics is a company based in Boston (United States) founded in 2019 by Samir Mitragotri and Ravi Srinivasan. i2o Therapeutics has raised $53.5 million across 6 funding rounds from investors including Colorcon, Sanofi Ventures and T1D Fund. The company has 6 employees as of December 31, 2021. i2o Therapeutics operates in a competitive market with competitors including Lyndra, Biora Therapeutics, Cure Pharmaceutical, Cingulate and OnDosis, among others.
- Headquarter Boston, United States
- Employees 6 as on 31 Dec, 2021
- Founders Samir Mitragotri, Ravi Srinivasan
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name I2o Therapeutics, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$53.5 M (USD)
in 6 rounds
-
Latest Funding Round
$3.5 M (USD), Series A
Oct 18, 2023
-
Investors
Colorcon
& 2 more
-
Employee Count
6
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of i2o Therapeutics
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of i2o Therapeutics
i2o Therapeutics has successfully raised a total of $53.5M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $3.5 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in i2o Therapeutics
i2o Therapeutics has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Colorcon, Sanofi Ventures and T1D Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life-Sciences focused Early stage Corporate VC Firm investing in the US
|
Locked | Locked | Locked | |
|
Companies developing T1D products are funded through venture philanthropy.
|
Locked | Locked | Locked | |
|
Developer of specialty excipients and corporate-backed venture capital fund focused on healthcare startups
|
Locked | Locked | Locked |
Investor details for i2o Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by i2o Therapeutics
Investment portfolio details for i2o Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - i2o Therapeutics
Detailed financials for i2o Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
I2o Therapeutics Comparisons
Peer comparison for i2o Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of i2o Therapeutics
i2o Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Lyndra, Biora Therapeutics, Cure Pharmaceutical, Cingulate and OnDosis, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Innovates long-acting oral therapies to simplify patient medication regimens.
|
|
| Locked | Locked | Locked |
Smart pills are developed for targeted gastrointestinal drug delivery.
|
|
| Locked | Locked | Locked |
Oral thin film-based drug delivery systems are developed.
|
|
| Locked | Locked | Locked |
Cingulate is focused on developing treatments for ADHD and anxiety.
|
|
| Locked | Locked | Locked |
Oral drug delivery systems for individualized micro-unit dosing are developed.
|
Detailed competitors of i2o Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on I2o Therapeutics
Complete news archive for i2o Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about i2o Therapeutics
i2o Therapeutics was founded in 2019 and raised its 1st funding round 1 year after it was founded.
i2o Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
i2o Therapeutics is a funded company, having raised a total of $53.5M across 6 funding rounds to date.
As of Dec 31, 2021, the latest employee count at i2o Therapeutics is 6.
i2o Therapeutics was founded in 2019 in Boston, United States, as a biotechnology firm focused on drug delivery systems. A liquid platform is utilized by the company to enable oral administration of therapeutics. Drug molecules are protected within this technology, while permeation across the epithelial lining is enhanced for better absorption. Operations center on developing this solution for pharmaceutical applications in the oral delivery sector.
i2o Therapeutics's top competitors include Cingulate, Cure Pharmaceutical and PLx Pharma.
i2o Therapeutics has 3 investors. Key investors include Colorcon, Sanofi Ventures, and T1D Fund.